Device Trial Radar · NCT07098195
To Evaluate the Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System
Last checked: Nov 20, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Aug 18, 2025
Primary completion
Aug 17, 2027
Study completion Jan 17, 2028
Sponsor
- Lead sponsor
- Poly Medicure LimitedNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 1, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the performance and safety of RisoR Crest Everolimus Eluting Coronary Stent System. A total of 2000 participants will be included in the study from India and Italy.
Conditions
- Coronary Artery Disease
- Coronary Artery Stenosis
- Percutaneous Coronary Intervention
- de Novo Lesions in Native Coronary Arteries
Interventions
Coronary StentDevice
RisoR Crest Everolimus Eluting Coronary Stent System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Target Lesion Failure (TLF)Time frame: 360 Days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.